Wilms tumor 1 peptide vaccination against relapseed or recurrence glioblastoma: safety and impact on immunological response

Research Project

Project/Area Number	26860797
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Multi-year Fund
Research Field	Pediatrics
Research Institution	Osaka University
Principal Investigator	Saitou Hiroyuki 大阪大学, 医学部附属病院, 医員 (00723909)
Project Period (FY)	2014-04-01 – 2016-03-31
Project Status	Completed (Fiscal Year 2015)
Budget Amount *help	¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000) Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000) Fiscal Year 2014: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Keywords	悪性神経膠腫 / 免疫療法 / 免疫治療 / 小児高悪性度神経膠腫 / 臨床研究 / WT1ペプチドワクチン
Outline of Final Research Achievements	Result of our department was transferred to company and it induced the clinical trial by company. So we studied the expression of PD-1 on the lymphocyte of these patients, and the proportion of the regulatory T cells in these patients. We clarified the high expression of PD-1 was found on lymphocytes of patients with relapse. These findings suggested that the immunocombined therapy consisting with WT1 and immunocheckpoint inhibitors is hopeful treatment for these patient with very intractable of brain tumor.